The reported data showed that DYNC1H1 was overexpressed in gastric cancer cell lines resistant to 5‐fluorouracil, paclitaxel, and cisplatin, suggesting that DYNC1H1 may be used as a biomarker for predicting chemotherapy efficacy in gastric cancer.30 Here, DYNC1H1 is linked to gastric cancer.